Asia Pacific Molecular Quality Controls Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Independent Controls, and Instrument Specific Controls), Analyte Type (Single Analyte Controls, and Multi Analyte Controls), Application (Infectious Diseases, Oncology, Genetic Testing, and Other Applications), and End User (Clinical Laboratories, Hospitals, IVD Manufacturers & Contract Research Organizations, Academic & Research Institutes, and Other End Users)
The Asia Pacific molecular quality controls market is expected to reach US$ 72.07 million in 2028 from US$ 34.27 million in 2021; it is estimated to grow at a CAGR of 11.2% from 2021 to 2028.
Factors such as burgeoning demand for personalized medicines, declining cost of sequencing procedures, and increasing prevalence of genetic diseases fuel the growth of the market. However, the dearth of skilled professionals hinders the market growth.
According to the WHO suggestions, 30–50% of deaths caused due to cancer can be prevented by adequate treatment in early stages. In this scenario, personalized medicine offers the most promising approach to tackle diseases that have not been well-known for responding effectively to the existing treatments or cures. Further, digitization is enabling doctors to make decisions about a patient’s cancer treatment, based on the genetic make-up of tumors or cancerous tissues. Thus, these advancements are making personalized medicine a reality by enabling the development of highly targeted therapies that offer the potential for improved treatment outcomes, especially for cancer patients. Moreover, personalized medicine considers genetic, environmental, and lifestyle variability. Hence, the increasing adoption of personalized medicines, based on patient’s genetic information, for disease treatments is expected to emerge as a notable trend in the molecular quality controls market in the coming years. Also, the cost of genome sequencing, as well as next-generation sequencing, has dropped radically in the past 6–7 years. Moreover, the process requires a lesser number of days for completion. Lowering costs and accelerating overall process enable service providers to secure larger profit margins, along with helping them expand their clientele. Thus, the lowered cost of genome sequencing is propelling the number of molecular biology procedures carried out for different purpose, thereby driving the use of molecular quality controls.
The Asia Pacific region is highly affected by the outbreak of the COVID-19 pandemic. Rising prevalence of COVID-19 and launch of PCR tests for detection COVID-19 support the growth of the market in near future forecast period. Growing initiative for quality assurance in the region is also likely to favor market growth. For instance, in India, Indian Council of Medical Research allocated 30 quality control (QC) laboratories to verify results of other laboratories in their respective areas. This helped in establishing quality of diagnosis. Therefore, the outbreak of the COVID-19 pandemic is estimated to affect high impact on Asia Pacific molecular quality controls industry.
The Asia Pacific molecular quality controls market, by product, is segmented into independent controls and instrument specific controls. The independent controls segment held a larger share of the market in 2020 whereas the same is anticipated to register the highest CAGR in the market during the forecast period.
Based on analyte type, the Asia Pacific molecular quality controls market has been segmented into single analyte controls and multi-analyte controls. The single analyte controls segment held a larger share of the market in 2020, whereas the multi-analyte control segment is estimated to register the highest CAGR in the market during the forecast period.
The Asia Pacific molecular quality control market, by application, is segmented into, infectious diseases, oncology, genetic testing, and other applications. The infectious diseases segment held the largest share of the market in 2020, whereas the oncology segment is anticipated to register the highest CAGR in the market during the forecast period.
Based on end user, the Asia Pacific molecular quality control market is segmented into clinical laboratories, hospitals, IVD manufacturers & contract research organizations, academic & research institutes, and other end users. The clinical laboratories segment held the largest share of the market in 2020 and is estimated to register the highest CAGR in the market during the forecast period.
A few of the primary and secondary sources associated with this report on the Asia Pacific molecular quality control market are the Beijing Genomics Institute (BGI), Biotechnology Industry Research Assistance Council (BIRAC), National Center for Biotechnology Information (NCBI), and Center for Cancer Genomics and Advanced Therapeutics (C-CAT).
Reason To Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific molecular quality controls market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the North America Asia Pacific molecular quality controls market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook